US 7,495,116 B2
Phospholipid derivative
Chika Itoh, Kanagawa (Japan); Kazuhiro Kubo, Kanagawa (Japan); Syunsuke Ohhashi, Kanagawa (Japan); Tohru Yasukohchi, Kanagawa (Japan); Hiroshi Kikuchi, Tokyo (Japan); Norio Suzuki, Chiba (Japan); Miho Takahashi, Fujieda (Japan); and Hitoshi Yamauchi, Tokyo (Japan)
Assigned to NOF Corporation, Tokyo (Japan); and Daiichi Pharmaceutical Co., Ltd., Tokyo (Japan)
Appl. No. 10/508,704
PCT Filed Mar. 28, 2003, PCT No. PCT/JP03/03966
§ 371(c)(1), (2), (4) Date May 25, 2005,
PCT Pub. No. WO03/082882, PCT Pub. Date Oct. 09, 2003.
Claims priority of application No. 2002-093694 (JP), filed on Mar. 29, 2002.
Prior Publication US 2005/0220856 A1, Oct. 06, 2005
Int. Cl. C07C 9/02 (2006.01)
U.S. Cl. 554—78  [424/450; 554/79; 554/82] 13 Claims
 
1. A phospholipid derivative represented by the following general formula (1):

OG Complex Work Unit Drawing
wherein Z represents a residue of a compound having 3 to 10 hydroxyl groups; AO represents an oxyalkylene group having 2 to 4 carbon atoms; R1CO and R2CO independently represent an acyl group having 8 to 22 carbon atoms; X represents hydrogen atom, an alkali metal atom, ammonium or an organic ammonium; “a” represents an integer of 0 to 4; “b” represents 0 or 1; Q represents hydrogen atom or methyl group; m represents an average number of moles of the oxyalkylene group added; and m, k1, k2, and k3 are numbers satisfying the following conditions: 3≤m≤200, 9≤m×(k1+k2+k3)≤1000, 1≤k1≤2, 0≤k2≤9 and 0≤k3≤9, and 3≤k1+k2+k3≤10.